Hartnup Disease: A Comprehensive Medical Review
Introduction
Hartnup disease (also known as Hartnup disorder or pellagra-like dermatosis) is a rare autosomal recessive metabolic disorder characterized by impaired absorption and renal reabsorption of neutral amino acids, leading to niacin (vitamin B₃) deficiency and pellagra-like manifestations. Named after the Hartnup family from England, in whom the condition was first described in 1956, this disorder affects the transport of monoaminomonocarboxylic (neutral) amino acids, particularly tryptophan, in the small intestine and renal proximal tubules.[1][2][3][4][5]
According to the National Organization for Rare Disorders (NORD), Orphanet (ORPHA:2116), MSD Manual Professional Edition, and MedlinePlus (NIH), Hartnup disease is caused by mutations in the SLC6A19 gene encoding the B⁰AT1 neutral amino acid transporter. The estimated prevalence is approximately 1 in 30,000 individuals worldwide, though most affected individuals remain asymptomatic throughout life.[3][4][6][1]
The condition is characterized by the classic triad of pellagra-like symptoms: dermatitis, diarrhea, and dementia (the “3 Ds”), along with cerebellar ataxia and neutral aminoaciduria. Symptoms typically appear in childhood (ages 3-9 years) but can manifest as early as 10 days after birth or as late as early adulthood.[2][7][8][4][5]
Etiology and Genetics
Genetic Basis
Hartnup disease is caused by homozygous or compound heterozygous mutations in the SLC6A19 gene:[6][1][3]
Gene and Chromosomal Location:
- Gene: SLC6A19 (Solute Carrier Family 6 Member 19)
- Chromosomal location: 5p15.33
- Inheritance pattern: Autosomal recessive
- Protein product: B⁰AT1 (Broad neutral amino acid transporter 1)[5][1][6]
B⁰AT1 Protein Function:
According to molecular physiology studies, B⁰AT1 is a sodium-dependent neutral amino acid transporter expressed in intestinal and renal epithelial cells:[1][3]
- Intestinal expression: Brush border membrane of small intestinal enterocytes
- Renal expression: Apical membrane of proximal tubular cells
- Transport function: Facilitates uptake of neutral amino acids from intestinal lumen and renal filtrate
- ACE2 interaction: Requires angiotensin-converting enzyme 2 (ACE2) as a chaperone for proper trafficking and function[9]
Affected Amino Acids
B⁰AT1 transports the following neutral (monoaminomonocarboxylic) amino acids:[8][3][1]
- Tryptophan: Most clinically significant
- Alanine
- Asparagine
- Citrulline
- Glutamine
- Histidine
- Isoleucine
- Leucine
- Phenylalanine
- Serine
- Threonine
- Tyrosine
- Valine
Notably excluded: Proline and hydroxyproline (transported by different systems)[3][8]
Pathophysiology
The pathophysiological consequences of SLC6A19 mutations result from dual defects in intestinal absorption and renal reabsorption:[10][11][3]
Intestinal Malabsorption:
- Reduced amino acid uptake: Impaired absorption of neutral amino acids from dietary protein
- Bacterial metabolism: Unabsorbed amino acids metabolized by gut flora
- Toxic metabolites: Production of indoles, indican, and other tryptophan degradation products
- Systemic absorption: Some bacterial metabolites absorbed and excreted in urine[10][3]
Renal Tubular Dysfunction:
- Impaired reabsorption: Failure to reclaim filtered amino acids from glomerular filtrate
- Neutral aminoaciduria: Massive urinary loss of neutral amino acids
- Compensatory mechanisms: Other amino acid transport systems partially compensate[11][3]
Tryptophan Deficiency and Niacin Synthesis:
The central pathophysiological mechanism involves tryptophan metabolism:[2][1][3]
- Tryptophan as niacin precursor: 60 mg tryptophan = 1 mg niacin (niacin equivalent)
- Impaired conversion: Defective tryptophan-to-nicotinamide pathway
- Niacin deficiency: Insufficient niacin (vitamin B₃) for NAD⁺/NADP⁺ synthesis
- Cellular energy crisis: NAD⁺ essential for glycolysis, TCA cycle, oxidative phosphorylation
- Pellagra-like syndrome: Classic dermatitis, diarrhea, dementia triad[7][2]
Neurological Mechanisms:
Recent research has identified novel mechanisms for neurological manifestations:[9]
- Ependymal cell expression: Previously unrecognized SLC6A19 expression in brain ependymal cells
- CSF amino acid transport: B⁰AT1 may transport amino acids from cerebrospinal fluid into ependymal cells
- Direct CNS effects: Beyond systemic tryptophan deficiency
- Niacin role in ependyma: Potential direct effects on brain function[9]
Clinical Presentation
Demographics and Epidemiology
According to published data and rare disease databases:[4][6]
Prevalence and Incidence:
- Estimated prevalence: 1 in 30,000 individuals
- Newborn screening: Higher detection rate in screening programs
- Symptomatic cases: Only 10-20% of genetically confirmed cases develop symptoms
- Geographic distribution: Worldwide, no ethnic predilection[4][6]
Age and Gender:
- Age of onset: Typically 3-9 years, range 10 days to early adulthood
- Gender: Equal male-to-female ratio
- Penetrance: Variable, most remain asymptomatic[5][4]
Clinical Manifestations
Most individuals with biochemical evidence of Hartnup disease remain asymptomatic throughout life. Symptomatic cases present with pellagra-like features triggered by various stressors:[12][3][4]
Classic Triad: The “3 Ds” of Pellagra
1. Dermatitis:
The most common and distinctive clinical feature:[13][7][2]
Cutaneous Manifestations:
- Photosensitive rash: Symmetric, well-demarcated erythematous lesions on sun-exposed areas
- “Pellagrous glove and boot”: Characteristic distribution on hands and feet
- Casal’s necklace: Circumferential dermatitis around neck
- Distribution: Face (sparing upper eyelids and behind ears), neck, hands, forearms, dorsal feet, legs
- Appearance: Initially erythematous macules coalescing into well-marginated red, scaling plaques
- Evolution: Hyperpigmentation, thickening, crusting, fissuring
- Burning sensation: Intense burning or stinging, especially on soles
- Seasonal pattern: Typically appears in spring/summer with sun exposure[13][7][2]
Mucosal Changes:
- Glossitis: Red, swollen, painful tongue with papillary atrophy
- Angular cheilitis: Cracks at corners of mouth
- Stomatitis: Oral mucosal inflammation[7][2]
2. Diarrhea:
Gastrointestinal manifestations:[8][12][2]
- Chronic diarrhea: Intermittent or persistent loose stools
- Partial response: May improve with antimotility agents
- Malabsorption: Contributing to nutritional deficiency
- Bacterial overgrowth: From unabsorbed amino acids[2]
3. Dementia:
Neuropsychiatric features:[14][8][2]
- Cognitive impairment: Confusion, disorientation, memory problems
- Psychiatric symptoms:
- Anxiety and emotional lability
- Depression
- Psychosis with delusions and hallucinations
- Agitation and behavioral changes
- Reversibility: Typically improves with niacin supplementation[15][14][2]
Neurological Manifestations
Cerebellar Dysfunction:
Prominent neurological features:[14][3][8]
- Cerebellar ataxia: Unsteady, wide-based gait; limb incoordination
- Intention tremor: Trembling during voluntary movements
- Dysmetria: Inability to judge distances accurately
- Nystagmus: Involuntary eye movements
- Dysarthria: Slurred or abnormal speech[15][14]
Other Neurological Signs:
- Hypotonia: Decreased muscle tone in some patients
- Spasticity: Increased muscle tone (occasionally)
- Hyperreflexia: Brisk deep tendon reflexes
- Developmental delay: Delayed motor milestones in childhood-onset cases
- Headaches: Recurrent, may be severe
- Syncope: Collapsing or fainting episodes[3][8][15]
Severe Neurological Presentations:
Recent case reports document severe adult-onset cases:[16][14]
- Encephalopathy: Severe cognitive impairment requiring intensive care
- Spasticity: Marked increased muscle tone
- Polyneuropathy: Distal weakness and sensory loss
- Cachexia: Severe wasting from malnutrition
- Dramatic response: Rapid improvement with high-dose niacin and amino acid supplementation[16][14]
Ocular Manifestations
Reported in some patients:[4]
- Diplopia: Double vision
- Photophobia: Light sensitivity
- Nystagmus: Rhythmic eye movements
- Strabismus: Misaligned eyes[4]
Growth and Development
Physical Growth:
- Short stature: Below normal height for age
- Failure to thrive: Poor weight gain in infancy
- Delayed puberty: May occur in some cases[15][3]
Intellectual Development:
- Normal intelligence: Most patients have normal cognitive abilities when not experiencing acute attacks
- Intellectual disability: Rare, reported in some cases with poor nutrition or recurrent episodes[5][4]
Triggering Factors
Symptoms are precipitated by factors that increase metabolic demands or impair nutrition:[8][3][4]
- Sunlight exposure: Most common trigger for dermatitis
- Poor nutrition: Inadequate protein or vitamin intake
- Febrile illness: Infections increasing metabolic demands
- Physical stress: Intense exercise, surgery, trauma
- Emotional stress: Psychological stressors
- Medications: Sulfonamide antibiotics
- Pregnancy: Increased nutritional demands[12][3][4]
Diagnosis
Clinical Diagnostic Approach
The diagnosis of Hartnup disease should be considered in patients presenting with pellagra-like symptoms, especially in the absence of obvious nutritional deficiency:[2][3]
Clinical Criteria:
According to diagnostic protocols:[3][8][4]
- Pellagra-like dermatitis: Photosensitive rash on sun-exposed areas
- Neurological symptoms: Cerebellar ataxia, psychiatric changes
- Neutral aminoaciduria: Elevated urinary excretion of neutral amino acids
- Dietary history: Not consistent with severe nutritional pellagra
- Response to niacin: Dramatic improvement with supplementation
Laboratory Investigations
Urine Amino Acid Analysis:
The definitive diagnostic test:[12][8][3]
- Method: Quantitative amino acid chromatography
- Findings: Markedly elevated neutral amino acids in urine
- Tryptophan
- Alanine, asparagine, citrulline, glutamine
- Histidine, isoleucine, leucine
- Phenylalanine, serine, threonine
- Tyrosine, valine
- Normal: Proline and hydroxyproline (excluded)
- Pattern: Characteristic neutral aminoaciduria[8][3]
Urine Indole Metabolites:
Supportive evidence:[10][3]
- Indican: Elevated (bacterial tryptophan metabolite)
- Indoleacetic acid: Increased
- Indole-3-lactic acid: Present
- 5-hydroxyindoleacetic acid (5-HIAA): May be elevated[3]
Plasma Amino Acids:
- Typically normal or low-normal: Due to compensatory mechanisms
- May show reduced tryptophan: During acute episodes
- Other neutral amino acids: Variable[14][8]
Additional Laboratory Tests:
- Complete blood count: May show anemia (hypochromic microcytic)
- Niacin metabolites: Low urinary N-methylnicotinamide
- Albumin: May be reduced in severe cases
- Liver and renal function: Usually normal[2][8]
Molecular Genetic Testing
SLC6A19 Gene Sequencing:
Confirmatory diagnostic test:[1][8][3]
- Method: Complete gene sequencing
- Findings: Biallelic pathogenic variants (homozygous or compound heterozygous)
- Variants: Over 30 different mutations reported
- Interpretation: Requires clinical correlation, as genotype doesn’t predict symptomatology[6][1]
Imaging Studies
Not specific for Hartnup disease but may be helpful in symptomatic cases:[14]
- Brain MRI: Rule out structural causes of neurological symptoms; usually normal or non-specific changes
- EEG: May show diffuse slowing during acute encephalopathy[14]
Differential Diagnosis
Hartnup disease must be differentiated from other causes of pellagra-like syndrome:[7][8][4]
Primary Differential Diagnoses:
1. Nutritional Pellagra:
- Similarities: Identical dermatitis, diarrhea, dementia triad
- Key differences: Dietary history of severe niacin deficiency, no aminoaciduria
- Populations at risk: Maize-based diets (lacks bioavailable niacin), alcoholism, malnutrition
- Response: Improves with niacin, but dietary history distinguishes[7][2]
2. Other Aminoacidurias:
- Cystinuria: Cystine stones, different amino acid pattern
- Lysinuric protein intolerance: Growth failure, hepatosplenomegaly, dibasic aminoaciduria
- Iminoglycinuria: Benign, involves proline, hydroxyproline, glycine[8]
3. Other Causes of Photosensitive Dermatitis:
- Porphyria: Blistering, fragility, different urine findings
- Systemic lupus erythematosus: Autoantibodies, systemic features
- Dermatomyositis: Heliotrope rash, muscle weakness
- Drug-induced photosensitivity: Medication history[13][7]
4. Cerebellar Ataxia Syndromes:
- Friedreich ataxia: Progressive, cardiomyopathy, diabetes
- Spinocerebellar ataxias: Family history, genetic testing
- Multiple sclerosis: Relapsing-remitting course, MRI findings[8]
Management and Treatment
Treatment Philosophy
The management of Hartnup disease focuses on preventing niacin deficiency through supplementation and dietary optimization, along with symptomatic treatment of acute episodes:[1][3][8]
Treatment Goals:
- Prevent symptom development: Maintain adequate niacin stores
- Treat acute episodes: Rapidly reverse niacin deficiency
- Optimize nutrition: High-protein diet to compensate for losses
- Prevent triggers: Sun protection, avoid precipitants[12][3]
Nutritional Management
Niacin/Nicotinamide Supplementation:
The cornerstone of preventive and acute treatment:[7][3][8]
Preventive Dosing:
- Nicotinamide: 20-50 mg/day orally (preferred due to lack of flushing)
- Niacin: Alternative, but causes flushing at therapeutic doses
- Long-term: Daily supplementation for symptomatic patients
- Monitoring: Adjust dose based on symptom control[12][3][8]
Acute Episode Treatment:
World Health Organization recommendations for pellagra apply:[7]
- Nicotinamide: 100-300 mg/day in divided doses
- Duration: 3-4 weeks for acute episodes
- Route: Oral preferred; IV if severe or unable to take orally
- Response: Symptoms improve within days to weeks[2][14][7]
Severe Cases:
Recent reports of life-threatening presentations:[16][14]
- High-dose niacin: 100 mg twice daily
- High-protein formula: 3 g/kg body weight/day
- IV amino acid supplementation: 800 mg tryptophan daily
- Intensive support: ICU care for severe encephalopathy
- Dramatic response: Significant improvement within 1 week[16][14]
High-Protein Diet:
Essential to compensate for amino acid losses:[3][12]
- Protein intake: 1.5-2 g/kg body weight/day (higher than usual requirements)
- Protein quality: Complete proteins with all essential amino acids
- Frequent meals: Multiple small meals to optimize absorption
- Dietary counseling: Work with nutritionist familiar with metabolic disorders[17][12]
Sun Protection
Critical to prevent photosensitive dermatitis:[12][3][8]
- Protective clothing: Long sleeves, wide-brimmed hats, long pants
- Sunscreen: Broad-spectrum SPF 30+ or higher, reapply frequently
- Avoid peak sun: Stay indoors 10 AM – 4 PM
- Shade seeking: Use umbrellas, stay in shaded areas
- Lifelong: Sun protection required throughout life[3][12]
Medications to Avoid
Sulfonamide Antibiotics:
Contraindicated in Hartnup disease patients:[8][3]
- Sulfamethoxazole-trimethoprim: Can precipitate acute episodes
- Other sulfonamides: All should be avoided
- Alternative antibiotics: Use non-sulfonamide options[3][8]
Symptomatic Treatment
Dermatological Care:
- Emollients: For dry, scaly skin
- Topical corticosteroids: For inflamed lesions (short-term)
- Wound care: For fissures and crusted lesions
- Avoid irritants: Harsh soaps, perfumes[13][7]
Neuropsychiatric Support:
When indicated:[15][14]
- Antidepressants: For depression (SSRIs)
- Mood stabilizers: For emotional lability
- Antipsychotics: For acute psychosis (short-term)
- Physical therapy: For ataxia and coordination
- Occupational therapy: Activities of daily living support
- Psychological counseling: For emotional adjustment[15][14]
Monitoring
Regular Follow-up:
- Clinical assessment: Every 6-12 months when stable
- Growth monitoring: Height, weight in children
- Nutritional status: Dietary review, protein intake assessment
- Symptom surveillance: Early detection of exacerbations
- Compliance: Ensure adherence to niacin supplementation[17][8]
Laboratory Monitoring:
- Urinary amino acids: Periodic monitoring (aminoaciduria persists despite treatment)
- Nutritional markers: Albumin, prealbumin if concerns
- Niacin status: Urinary N-methylnicotinamide (if available)[8]
Prognosis and Long-term Outcomes
Overall Prognosis
The prognosis for Hartnup disease is generally excellent with appropriate management:[12][3][8]
Life Expectancy:
- Normal lifespan: With niacin supplementation and dietary management
- Rare severe cases: Deaths reported in families with severe disease
- Quality of life: Can be excellent with proper treatment[12][3]
Natural History:
- Spontaneous improvement: Attacks typically become less frequent with age
- Adult remission: Many patients have fewer or no symptoms after adolescence
- Persistent aminoaciduria: Biochemical abnormality remains lifelong
- Pregnancy: Generally well-tolerated with continued supplementation[4][3][8]
Symptom-Specific Outcomes
Dermatological:
- Reversibility: Acute lesions resolve with niacin treatment within 1-2 weeks
- Chronic changes: Prolonged sun exposure can cause permanent hyperpigmentation
- Prevention: Sun protection and niacin prevent recurrence[13][7]
Neurological:
- Reversibility: Most neurological symptoms reverse with treatment
- Rare exceptions: Permanent deficits reported in severe, untreated cases
- Cognitive function: Usually returns to baseline
- Ataxia: Typically resolves completely[14][3][12]
Psychiatric:
- Resolution: Psychiatric symptoms improve with niacin supplementation
- Recurrence risk: Can recur with non-compliance or inadequate supplementation
- Long-term: Usually no persistent psychiatric issues[15][14]
Complications
Possible Complications:
Most can be prevented with appropriate treatment:[12]
- Permanent skin pigmentation changes: From chronic sun exposure
- Neurological sequelae: Rare, in severe untreated cases
- Psychiatric complications: If recurrent untreated episodes
- Social impact: From visible dermatitis, neurological symptoms[3][12]
Research Directions and Future Perspectives
Molecular Research
SLC6A19 and ACE2 Interaction:
Recent insights into B⁰AT1 function:[9]
- ACE2 as chaperone: Required for proper trafficking of B⁰AT1 to cell surface
- COVID-19 connection: ACE2 is SARS-CoV-2 receptor; potential implications for Hartnup patients
- Therapeutic targets: Modulating ACE2-B⁰AT1 interaction
- Tissue-specific expression: Understanding expression patterns beyond intestine and kidney[9]
Ependymal Cell Expression:
Novel findings about CNS involvement:[9]
- Brain expression: Previously unrecognized SLC6A19 in ependymal cells
- CSF amino acid transport: Potential role in brain amino acid homeostasis
- Direct CNS effects: May explain neurological symptoms beyond systemic deficiency
- Niacin in brain: Potential direct effects on ependymal function[9]
Clinical Research
Genotype-Phenotype Correlations:
- Mutation-specific effects: Understanding why some mutations cause symptoms while others don’t
- Modifier genes: Identifying genetic factors influencing penetrance
- Environmental interactions: How diet, sun exposure, stress interact with genotype[1][4]
Natural History Studies:
- Long-term outcomes: Systematic follow-up of diagnosed patients
- Asymptomatic carriers: Understanding why most remain symptom-free
- Pregnancy outcomes: Effects on maternal and fetal health[17][4]
Therapeutic Development
Novel Treatment Approaches:
- Targeted amino acid supplementation: Specific formulations to bypass defect
- Gut microbiome modulation: Reducing bacterial amino acid metabolism
- Gene therapy: Future possibility for correcting B⁰AT1 deficiency
- Pharmacological chaperones: Enhancing residual B⁰AT1 function[1]
Preventive Strategies:
- Newborn screening: Early identification for preventive intervention
- Dietary optimization: Specialized formulas for symptomatic infants
- Preemptive supplementation: Before symptom onset in diagnosed individuals[17][4]
Conclusion
Hartnup disease represents a fascinating disorder of amino acid transport that illustrates the critical importance of adequate tryptophan availability for niacin synthesis and overall health. Since its initial description in the Hartnup family in 1956, our understanding has evolved from a purely clinical entity to a well-characterized molecular disorder with an identified genetic cause in the SLC6A19 gene.
The paradox of Hartnup disease—that most individuals with the genetic defect remain asymptomatic while a minority develop severe pellagra-like manifestations—highlights the complex interplay between genetics, nutrition, and environmental factors in disease expression. The recognition that dietary protein intake, sun exposure, physical stress, and intercurrent illness can precipitate symptomatic episodes underscores the importance of lifestyle modifications and preventive supplementation in affected individuals.
The dramatic response to niacin supplementation in symptomatic patients, with resolution of dermatitis, diarrhea, and neuropsychiatric symptoms within days to weeks, demonstrates the direct causative role of niacin deficiency in disease manifestations. Recent case reports of severe adult-onset presentations successfully treated with high-dose niacin and protein supplementation emphasize that Hartnup disease should be considered in the differential diagnosis of unexplained pellagra-like symptoms, even in adults.
The recent discovery of SLC6A19 expression in brain ependymal cells suggests that the neurological manifestations of Hartnup disease may involve direct CNS effects beyond systemic tryptophan deficiency. This finding opens new avenues for research into the pathophysiology of neurological symptoms and may lead to novel therapeutic approaches targeting brain amino acid homeostasis.
The excellent prognosis for most patients with Hartnup disease, particularly those who receive early diagnosis and appropriate supplementation, is reassuring. The tendency for symptoms to decrease with age and the general preservation of normal intelligence and life expectancy support an optimistic outlook for affected individuals. However, the recognition that severe, life-threatening presentations can occur emphasizes the importance of maintaining awareness of this condition among healthcare providers.
Looking forward, continued research into the molecular mechanisms of B⁰AT1 function, its interaction with ACE2, and tissue-specific expression patterns will likely yield insights not only into Hartnup disease but also into normal amino acid homeostasis and potential therapeutic targets for other metabolic disorders. The application of newborn screening programs may enable early identification and preventive intervention before symptom onset, further improving outcomes.
Healthcare providers should maintain awareness of Hartnup disease when evaluating patients with photosensitive dermatitis, cerebellar ataxia, and neuropsychiatric symptoms, particularly when accompanied by neutral aminoaciduria. Early diagnosis, niacin supplementation, high-protein diet, and sun protection can prevent complications and enable affected individuals to live normal, healthy lives.
Sources
- https://rarediseases.org/rare-diseases/hartnup-disease/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC2784584/
- https://www.msdmanuals.com/professional/pediatrics/inherited-disorders-of-metabolism/hartnup-disease
- https://www.orpha.net/en/disease/detail/2116
- https://en.wikipedia.org/wiki/Hartnup_disease
- https://medlineplus.gov/genetics/condition/hartnup-disease/
- https://dermnetnz.org/topics/pellagra
- https://www.msdmanuals.com/en-jp/professional/pediatrics/inherited-disorders-of-metabolism/hartnup-disease
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10123343/
- https://www.merckmanuals.com/professional/pediatrics/inherited-disorders-of-metabolism/hartnup-disease
- https://www.merckmanuals.com/en-ca/professional/pediatrics/inherited-disorders-of-metabolism/hartnup-disease
- https://medlineplus.gov/ency/article/001201.htm
- https://www.sciencedirect.com/topics/medicine-and-dentistry/hartnup-disease
- https://www.neurology.org/doi/10.1212/NXG.0000000000200195
- https://www.healthline.com/health/hartnup-disorder
- https://www.acpjournals.org/doi/10.7326/aimcc.2024.0137
- https://metabolicsupportuk.org/condition/hartnup-disease/
- https://www.msdmanuals.com/home/children-s-health-issues/hereditary-metabolic-disorders/hartnup-disease
- https://medicoapps.org/hartnup-ds-2/
- https://my.clevelandclinic.org/health/diseases/23905-pellagra
